News Focus
News Focus
Followers 99
Posts 13186
Boards Moderated 0
Alias Born 06/01/2013

Re: Phosphene post# 20984

Tuesday, 11/03/2020 3:03:17 PM

Tuesday, November 03, 2020 3:03:17 PM

Post# of 27661
From that, TRANSVAC2 will function as leverage and innovation catalyst between all stakeholders involved in vaccine R&D in Europe and -by providing integrated and overarching vaccine R&D services- will contribute to the development of effective products to address European and global health challenges, to controlling the burden and spread of infectious diseases, and reinforce the economic assets represented by vaccine developers in Europe.

CONSORTIUM AGREEMENT

Shall mean the model grant agreement established by the Commission for the undertaking of collaborative projects under the Community’s Seventh Framework Programme (FP7).

CONTRACTOR #13- Mymetics:

Mymetics Corp. owns the IP on the virosome technology in the field of HIV and malaria. Meanwhile, Mymetics Corp. grants to Mymetics Management Sàrl, a Swiss subsidiary of Mymetics Corps, the right to use its Background under certain restrictions for performing the project described into the NGIN Consortium Agreement (FP7). Mymetics Corp. hereby excludes from its obligation to grant Access Right to its Background acquired by its various academic and private collaborators related to research programs on antigen designs, antigen production, virosome, vaccine development and production. These exclusions especially concern the collaboration with Dr Morgane Bomsel (UPD, contractor no.15) on the development of a virosome-based mucosal vaccine against HIV, based on the gp41 antigen, and Dr. Erwann Loret (Marseille University, France).. These exclude especially the following patents

CYTOS BIOTECHNOLOGY AG , whose main administrative office is at Wagistrasse 25 , CH-8952 Zurich-Schlieren, Switzerland; represented by Dr. Martin Bachmann, Chief Scientific Officer, duly authorised for the purposes hereof;
- Hereinafter referred to as “Cytos”

Authorised to sign on behalf of CYTOS BIOTECHNOLOGY AG (CYTOS)
By (signature):
Name: Dr. Martin Bachmann
Title: Chief Scientific Officer

& a whole lot more in that which I have posts on

Hang in there Brother b/c this lil jewel predates anyone posting here or does it ?

https://www.sec.gov/Archives/edgar/data/927761/000095015208001236/l30222aexv10w1.htm

GO BEARS if ya know what I mean





Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y